|1.||Dieckgraefe, Brian K: 3 articles (01/2008 - 05/2005)|
|2.||Hodi, F Stephen: 2 articles (09/2015 - 11/2014)|
|3.||Fong, Lawrence: 2 articles (09/2015 - 06/2006)|
|4.||Small, Eric J: 2 articles (09/2015 - 06/2006)|
|5.||Weinberg, Vivian: 2 articles (09/2015 - 06/2006)|
|6.||Dreicer, Robert: 2 articles (01/2014 - 05/2008)|
|7.||Triozzi, Pierre: 2 articles (01/2014 - 05/2008)|
|8.||Elson, Paul: 2 articles (01/2014 - 05/2008)|
|9.||Garcia, Jorge A: 2 articles (01/2014 - 05/2008)|
|10.||Chande, Nilesh: 2 articles (07/2012 - 01/2011)|
|1.||Crohn Disease (Crohn's Disease)
01/01/2011 - "Sargramostim does not appear to be more effective than placebo for induction of clinical remission or clinical improvement in patients with active Crohn's disease. "
10/01/2009 - "Sargramostim was more effective than placebo for inducing corticosteroid-free remission in patients with Crohn's disease with corticosteroid dependence. "
01/01/2008 - "Clinical trials show that sargramostim induces clinical response and remission in patients with active Crohn's disease. "
05/26/2005 - "This study was negative for the primary end point, but findings for the secondary end points suggest that sargramostim therapy decreased disease severity and improved the quality of life in patients with active Crohn's disease."
01/01/2009 - "We aimed to assess the tolerability, pharmacokinetics, safety, and efficacy of sargramostim in Japanese patients with active Crohn's disease (CD). "
|2.||Melanoma (Melanoma, Malignant)
12/01/2008 - "A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study."
12/01/2008 - "Early testing of aerosolized sargramostim therapy demonstrated anecdotal clinical responses in patients with metastatic melanoma associated with emergence of systemic antitumor immunity. "
08/01/2007 - "Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence."
07/01/2009 - "A hypothesis generating study was conducted to evaluate the safety and efficacy of prolonged (3 y) administration of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) as surgical adjuvant therapy in patients with melanoma at high risk of recurrence. "
01/01/2002 - "The author's group has conducted trials of granulocyte-macrophage colony-stimulating factor (GM-CSF [Leukine]) as surgical adjuvant treatment of patients at high-risk for melanoma recurrence. "
04/01/2001 - "Poor QOL caused by infection and increased length of hospital stay is expected to be improved by sargramostim. "
01/01/2007 - "The limited experience with rhGM-CSF for the treatment of invasive fungal infections in combination with antifungal drug(s) was associated with a favorable outcome, and in contrast to Escherichia coli-derived rhGM-CSF, the new preparation (sargramostim) was well tolerated and rarely associated with serious systemic toxicities. "
07/01/1997 - "The high cost of sargramostim and other myeloid growth factors and their ability to reduce infections and days of hospitalization have generated interest in their pharmacoeconomic impact. "
12/01/1994 - "In 7 of 17 patients treated for metastatic breast cancer with HDCT and PBPC within 6 consecutive months, neutropenic fever without signs of infection was observed, which may be sargramostim-related fever. "
12/01/1994 - "The typical presentation must fulfil the following criteria: cyclical elevation in body temperature that happens at the predicted time after sargramostim administration; absence of other signs or symptoms of infections; quick resolution of the fever after onset acetaminophen administration. "
07/01/1997 - "Sargramostim is a myeloid growth factor that is widely used as adjunctive support in patients with neutropenia. "
07/01/1997 - "More data regarding the use of sargramostim for chemotherapy-induced neutropenia are required to properly assess the pharmacoeconomic impact in these patients."
07/01/1997 - "Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy."
12/15/1999 - "Studies have shown both filgrastim and sargramostim to be effective in treating neutropenia in HIV-infected patients without increasing the viral load. "
12/15/1999 - "Both filgrastim and sargramostim show promise in treating and preventing neutropenia in HIV-infected patients. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
07/01/1997 - "Cost minimization studies in patients receiving chemotherapy for acute myelogenous leukemia and in recipients of autologous bone marrow transplantation (BMT) show estimated cost savings with sargramostim of 1996 US$12,513 and 1994 US$14,500, respectively. "
07/01/2004 - "We report a case of Sweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia. "
07/01/2015 - "Individuals with WT1-positive acute myeloid leukemia (AML) in first (CR1) or second (CR2) remission or with higher-risk myelodysplastic syndrome (MDS) following at least 1 prior line of therapy were vaccinated with a mixture of peptides derived from the WT1 protein, with sargramostim injections before vaccination to amplify immunogenicity. "
01/01/2001 - "The following search terms were used: granulocyte colony-stimulating factor, filgrastim, granulocyte-macrophage colony-stimulating factor, sargramostim, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute nonlymphocytic leukemia, and acute myeloid leukemia. "
04/01/2005 - "In this study, we utilized these synergistic effects of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]), hydroxyurea, and low-dose cytosine arabinoside to treat elderly patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). "
|1.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|4.||Granulocyte Colony-Stimulating Factor (G-CSF)
|8.||severe chronic Neutropenia
|1.||Drug Therapy (Chemotherapy)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|5.||Stem Cell Transplantation